Ideas Semilla AECC 2020
Research project
Presentation deadline closed (23/06/2020 - 22/06/2022 00:00)
Description
The present AECC Semilla proposal aims at setting up, testing and validating a novel Cardiac Toxicity Device (CTD). This new platform emerges from the combination of the latest microfabrication technology with relevant human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs). hiPSC-CMs faithfully recapitulate the features of a patient´s cardiac cells, specially pharmacological sensitivity. With this project we will provide proof-of-concept of the feasibility of our proposed CTD. On a first stage, we will test the capacity of the platform to reproduce the toxicity of known anti-cancer drugs (doxorubicin, daunorubicin, sunitinib and sorafenib). The project will progress in the automation of the analysis, as well as in expanding the applicability to more healthy as well as diseased hiPSC lines. Finally, we will determine the relevance of our device to perform in high throughput by increasing the number of compounds, and to detect the presence of immune checkpoint inhibitor therapy derived cardiotoxicity with serological patients´ samples. All in all, we expect this AECC Semilla project to plant the seeds of a revolutionary system to assess anti-cancer therapy related cardiac toxicity.
Budget
€9700